SEE UPDATE FROM OCTOBER 30, 2023 HERE CLICK BELOW FOR A FEW WORDS FROM OUR TEAM AND SAREPTA: Sarepta Therapeutics’ gene therapy for Duchenne, SRP-9001, has been granted Accelerated Approval […]
NEW YORK, June 15, 2023 – CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative clinical trial grant to test repurposing of the FDA-approved […]
Tickets and Sponsorships Available in Support of Nonprofit Dedicated to Finding and Funding Cure for Duchenne Muscular Dystrophy Knoxville, TN. (June 5, 2023) – Knoxville Brewfest, the city’s most anticipated […]
“CureDuchenne is a leader in funding pioneering research aimed at advancing the best possible therapies for DMD patients, and we value their vote of confidence and financial support of our snRNA-mediated exon skipping platform,” said Jim Burns, Ph.D., Locanabio’s chief executive officer.
My name is Debra Miller, founder and CEO of CureDuchenne, and the mother of an incredible son, Hawken, who has Duchenne muscular dystrophy. I’m here today to represent the voice of patient advocacy organizations serving those impacted by Duchenne – all of whom are in support of the accelerated approval of SRP-9001.
Newport Beach, Calif. (May 11, 2023) – CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD). […]
There is no way to be a normal parent, when you have abnormal circumstances. The important thing is that you keep getting up every day loving those kids. You may think it’s not enough, but your children see you differently than you see yourself. I have days that I feel like super mom and days that I feel like a huge failure. “It’s just too hard,” I mumble to myself as I crawl into bed at night unsure of how I will possibly do the whole thing again tomorrow.
CureDuchenne Ventures announces an investment in Insmed Inc. to support the development of INS1201, their next generation intracerebroventricular (ICV) delivered AAV to directly address limitations of current gene therapy approaches.
See the below letter to the community
